Concentrix Corporation

NasdaqGS:CNXC Stok Raporu

Piyasa değeri: US$1.7b

Concentrix Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Concentrix şirketinin toplam hissedar öz sermayesi $2.7B ve toplam borcu $4.6B olup, bu da borç-öz sermaye oranını 169.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $10.5B ve $7.8B dir. Concentrix 'in FAVÖK'ü $620.7M faiz karşılama oranı 2.2 dur. Şirketin $255.6M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

169.73%

Borç/özkaynak oranı

US$4.58b

Borç

Faiz karşılama oranı2.2x
NakitUS$255.57m
EşitlikUS$2.70b
Toplam yükümlülüklerUS$7.81b
Toplam varlıklarUS$10.51b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Seeking Alpha • Sep 18

Concentrix: This AI Bargain Stock Could Be The Ultimate Value Trap - Strong Sell

Summary Concentrix appears deeply undervalued on adjusted free cash flow metrics relative to its sub-$2 billion market cap, but I think its valuations are a trap. Despite attractive valuation, CNXC’s AI initiatives may be cannibalizing its traditional revenue streams, complicating the investment case. Recent financials suggest CNXC’s AI-driven cost reductions could undermine its own growth prospects. I remain bearish, as the company’s strategic shift raises concerns about long-term revenue sustainability. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Sep 17

CNXC: Guidance Reset And Risk Expansion Will Shape Earnings Path Forward

Concentrix now carries an updated analyst fair value estimate of $30.00, up from $26.00, with analysts pointing to revised long term assumptions on revenue growth and profit margins following recent price target resets in the $26 to $45 range. Analyst Commentary Recent Street research on Concentrix shows a clear tilt toward more cautious expectations, with several bearish analysts trimming price targets after the latest fiscal Q2 report.
Anlatı Güncellemesi • Jul 21

CNXC: Guidance Reset And Investigation Will Shape Earnings Trajectory

For Concentrix, the analyst fair value estimate has been reduced from $54.00 to $26.00. Analysts cited softer revenue assumptions, higher discount rates, and updated earnings forecasts following fiscal Q2 results and revised guidance.
Anlatı Güncellemesi • Jul 07

CNXC: Reset Expectations And Index Shift Will Support Future Upside Potential

Analysts have lowered the Concentrix fair value estimate from $41.25 to $35.25, reflecting reduced long term revenue growth assumptions. Profit margin expectations and the future P/E input also shift in response to updated models following recent Q2 results and guidance.
Anlatı Güncellemesi • Jun 23

CNXC: Margin Resilience And Index Shift Will Support Repriced Upside Potential

Analysts have trimmed their price targets on Concentrix by $12 to $25, citing updated assessments of the company’s outlook while keeping key assumptions such as fair value at $41.25 and long term revenue growth and profit margin broadly unchanged. Analyst Commentary Recent research on Concentrix points to a more cautious stance on valuation, with several firms trimming price targets while keeping long term growth and margin assumptions broadly intact.
Anlatı Güncellemesi • Jun 07

CNXC: Margin Expansion And Buybacks Will Support Repriced Upside Potential

Analysts have reduced their price targets on Concentrix by $12 to $25, citing updated views on the company’s outlook. They maintained their fair value estimates and kept key model inputs such as discount rate, revenue growth, profit margin, and future P/E broadly unchanged.
Anlatı Güncellemesi • May 13

CNXC: Margin Resilience And Buybacks Will Support Repriced Upside Potential

Concentrix's analyst price target has been revised lower by a combined $24 to $25 across several firms, with analysts citing updated views on valuation and business outlook to support the adjustment. Analyst Commentary Across the latest research updates, analysts reduced their price targets for Concentrix by amounts ranging from $12 to $25, pointing to reassessments of valuation and the business outlook.
Anlatı Güncellemesi • Apr 25

CNXC: Margin Resilience And Buybacks Will Support Future Upside Potential

Analysts have trimmed their Concentrix price targets by $12 to $25, citing more conservative assumptions around future P/E multiples, while keeping fair value, discount rate, and margin expectations broadly unchanged. Analyst Commentary Bullish Takeaways Bullish analysts appear to see the P/E reset as a way to align expectations more closely with current sentiment, which can reduce the risk of overpaying for near term execution.
Anlatı Güncellemesi • Apr 10

CNXC: Higher Margin Outlook And Buybacks Will Support Future Upside Potential

Narrative Update The updated analyst price target for Concentrix moves from approximately $48.60 to about $41.25. This reflects recent cuts from several firms as analysts point to more measured revenue growth assumptions, offset by slightly higher projected profit margins and a lower future P/E multiple.
Anlatı Güncellemesi • Mar 27

CNXC: Higher Margin Outlook And Buybacks Will Support Future Undervalued Entry

The analyst price target for Concentrix has shifted from $62.20 to $48.60. Analysts attribute this change to updated assumptions around slower revenue growth, a higher profit margin profile, and a lower future P/E multiple following recent target cuts from Barrington, Baird, and Canaccord.
Anlatı Güncellemesi • Mar 12

CNXC: AI Rollout And Buybacks Will Support Future Undervalued Entry

Analysts have trimmed their price target on Concentrix by $4, reflecting updated views captured in recent research while keeping key fair value and growth assumptions essentially unchanged. Analyst Commentary Recent research around the $4 reduction in the price target highlights a mix of confidence in Concentrix’s core thesis and a more cautious stance on execution and risk.
Anlatı Güncellemesi • Feb 26

CNXC: Higher Discount Rate Assumptions Will Support Future Undervalued Entry

Analysts have trimmed their price target on Concentrix by $4, reflecting updated assumptions around discount rates and valuation multiples, while keeping fair value estimates for the business broadly unchanged. Analyst Commentary Analysts describe the $4 price target cut as a fine tuning of their models rather than a reset of their overall view on Concentrix, with fair value estimates broadly intact.
Analiz Makalesi • Feb 16

Benign Growth For Concentrix Corporation (NASDAQ:CNXC) Underpins Stock's 30% Plummet

Concentrix Corporation ( NASDAQ:CNXC ) shareholders won't be pleased to see that the share price has had a very rough...
Anlatı Güncellemesi • Feb 12

CNXC: Updated Discount Rate Assumptions Will Support Future Undervalued Entry

Analysts have lowered their price target on Concentrix by $4, citing updated assumptions around discount rates and profitability, while keeping fair value estimates broadly stable. Analyst Commentary Analysts describe the recent US$4 reduction in the price target as a fine tuning of their view, reflecting updated discount rate assumptions and a more cautious stance on profitability, rather than a fundamental reset of Concentrix's underlying worth.
Anlatı Güncellemesi • Jan 29

CNXC: Updated Discount Rate And P/E Assumptions Will Support Future Undervalued Entry

Narrative Update on Concentrix Analysts have trimmed their price target on Concentrix by $4, citing updated assumptions around discount rates and future P/E expectations, while keeping their fair value estimate unchanged at $62.20. Analyst Commentary Recent research around Concentrix reflects a mixed tone, with the $4 trim to the price target tied mainly to updated discount rate inputs and revised P/E assumptions rather than a reset of the underlying fair value, which remains at $62.20.
Anlatı Güncellemesi • Jan 15

CNXC: Higher Discount Rate Reset Will Support Future Undervalued Entry Thesis

Analysts have trimmed their price target on Concentrix by about $2.63, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E following recent research that included a $4 reduction highlighted at Baird. Analyst Commentary Analysts framing the new price target are trying to line up their fair value work with updated assumptions on discount rates, revenue growth, margins and the future P/E they think the market is willing to pay for Concentrix.
Analiz Makalesi • Nov 08

Concentrix Corporation (NASDAQ:CNXC) Not Doing Enough For Some Investors As Its Shares Slump 28%

The Concentrix Corporation ( NASDAQ:CNXC ) share price has fared very poorly over the last month, falling by a...
Analiz Makalesi • Sep 29

Concentrix's (NASDAQ:CNXC) Upcoming Dividend Will Be Larger Than Last Year's

The board of Concentrix Corporation ( NASDAQ:CNXC ) has announced that it will be paying its dividend of $0.36 on the...
Anlatı Güncellemesi • Sep 27

AI Integration And Webhelp Synergies Will Transform Business

Concentrix's consensus price target was modestly reduced to $64.83 as analysts factor in compressed valuation multiples from AI-related investor uncertainty and secular headwinds—rather than fundamental weakness—while maintaining confidence in growth reacceleration and strong business fundamentals. Analyst Commentary Compressed valuation multiples attributed to investor uncertainty over the impact of artificial intelligence on labor-intensive business models and broader secular headwinds, not due to fundamental company weakness.
Analiz Makalesi • Apr 03

Concentrix Corporation's (NASDAQ:CNXC) Shares Leap 26% Yet They're Still Not Telling The Full Story

The Concentrix Corporation ( NASDAQ:CNXC ) share price has done very well over the last month, posting an excellent...
Analiz Makalesi • Jan 29

The Market Lifts Concentrix Corporation (NASDAQ:CNXC) Shares 25% But It Can Do More

Concentrix Corporation ( NASDAQ:CNXC ) shareholders have had their patience rewarded with a 25% share price jump in the...
Seeking Alpha • Jan 17

Concentrix: Better Than Expected Results, GenAI, And Cheap

Summary Concentrix Corporation delivered better-than-expected EPS and revenue, driven by significant investments in its GenAI product suite and a booming AI customer experience market. The AI in customer experience market is projected to grow at a 22% CAGR, potentially boosting CNXC's future revenue and free cash flow growth. Despite risks from high debt levels and potential global tariffs, CNXC's substantial headcount growth and consistent net income make it appear undervalued. My financial model suggests CNXC is significantly undervalued, with an equity valuation of $6.5 billion and a target price of $102 per share. Read the full article on Seeking Alpha
Seeking Alpha • Dec 21

AI: Will Freshworks Leave Room For Concentrix?

Summary A.I. is revolutionising Customer Relationship Management (CRM), with Salesforce leading the market, leveraging Big Data to enhance customer interactions and sales conversions. Generative A.I. significantly boosts Customer Experience (CX) performance, with early adopters seeing a 25% increase in CX satisfaction, and the global CX market projected to grow to $33bn by 2030. Concentrix, with a $2.86bn market cap, offers comprehensive CX services including call centres. Freshworks is a SAAS only CX provider. Both companies have seen 70% plus share price declines, but one is still priced for growth, the other for business declines. Is this justified? Read the full article on Seeking Alpha

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CNXC 'nin kısa vadeli varlıkları ( $3.0B ) kısa vadeli yükümlülüklerini ( $2.6B ) aşıyor.

Uzun Vadeli Yükümlülükler: CNXC 'un kısa vadeli varlıkları ( $3.0B ) uzun vadeli yükümlülüklerini ( $5.2B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CNXC 'nin net borç/öz sermaye oranı ( 160.3% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: CNXC şirketinin borç/öz sermaye oranı son 5 yılda 37.9% seviyesinden 169.7% seviyesine yükseldi.

Borç Kapsamı: CNXC 'nin borcu işletme nakit akışı ( 16.2% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: CNXC 'in borcuna ilişkin faiz ödemeleri EBIT ( 2.2 x kapsam) tarafından iyi karşılanmıyor.

Bilanço

Sağlıklı şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/09/21 09:49
Gün Sonu Hisse Fiyatı2026/09/18 00:00
Kazançlar2026/05/31
Yıllık Kazançlar2025/11/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Concentrix Corporation 5 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
David KoningBaird
Vincent ColicchioBarrington Research Associates, Inc.
Ruplu BhattacharyaBofA Global Research